Skip to Main Content

Christine Higham

MD

Pediatric hematologist-oncologist
Bone marrow transplant specialist
Runner and lover of the outdoors

Dr. Christine Higham is a specialist in blood and bone marrow transplantation for pediatric patients.

Higham studies thrombotic microangiopathy, a serious condition that can develop after a bone marrow transplant. Her research aims to discover why this damage to blood vessels may occur and how to prevent it.

Higham earned her medical degree from Boston University School of Medicine. She completed a residency in pediatrics at Northwestern University Feinberg School of Medicine. She then completed a fellowship in pediatric hematology and oncology at Children's National Hospital and a fellowship in pediatric bone marrow transplantation at UCSF.

Higham is a member of the American Society of Clinical Oncology, American Society of Pediatric Hematology/Oncology and Phi Beta Kappa Society.

  • Education

    Boston University School of Medicine, 2010

  • Residencies

    Northwestern University Feinberg School of Medicine, Pediatrics, 2013

  • Fellowships

    UCSF, Pediatric Bone Marrow Transplantation, 2017

    Children's National Health System, Pediatric Hematology and Oncology, 2017

  • Academic Title

    Associate Professor

"Even in the hardest times, I say to my families 'I'm going to sit in this space of hope with you, and I'm with you.'"

Where I see patients (1)

    Decorative Caduceus

    Using Ultrasound Elastography to Predict Development of Hepatic Sinusoidal Obstruction Syndrome

    To define a threshold and quantify the sensitivity and specificity of US SWE for risk stratification of patients into three categories as defined by the EBMTC adult and pediatric criteria: no SOS, mild to moderate SOS, and severe ...

    Recruiting

    More about this study
    Decorative Caduceus

    The EndRAD Trial: Eliminating Total Body Irradiation (TBI) for NGS-MRD Negative Children, Adole...

    The primary objective of this study is the two Year Event-free Survival for patients with high-risk or recurrent B-ALL who proceed to HCT and who are NGS-MRD negative when treated with a non-TBI preparative regimen.

    Recruiting

    More about this study
    See all clinical trials

    Staff superheroes

    It’s a bird. It’s a plane. It’s a window washer! Dressed as a superhero to clean and brighten your day.

    Share